257 related articles for article (PubMed ID: 12638211)
1. [Development of bisphosphonates].
Nakatsuka K
Nihon Rinsho; 2003 Feb; 61(2):219-25. PubMed ID: 12638211
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates in the treatment of disorders of mineral metabolism.
Singer FR; Minoofar PN
Adv Endocrinol Metab; 1995; 6():259-88. PubMed ID: 7671099
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates: the first 40 years.
Russell RG
Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
5. Etidronate for hypercalcemia of malignancy and osteoporosis.
Horowitz E; Miller JL; Rose LI
Am Fam Physician; 1991 Jun; 43(6):2155-9. PubMed ID: 1904188
[TBL] [Abstract][Full Text] [Related]
6. Management of Paget's disease of bone.
Langston AL; Ralston SH
Rheumatology (Oxford); 2004 Aug; 43(8):955-9. PubMed ID: 15187244
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates in the treatment of metabolic bone diseases.
Rodan GA; Balena R
Ann Med; 1993 Aug; 25(4):373-8. PubMed ID: 8217103
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
Russell RG; Xia Z; Dunford JE; Oppermann U; Kwaasi A; Hulley PA; Kavanagh KL; Triffitt JT; Lundy MW; Phipps RJ; Barnett BL; Coxon FP; Rogers MJ; Watts NB; Ebetino FH
Ann N Y Acad Sci; 2007 Nov; 1117():209-57. PubMed ID: 18056045
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy.
Li B; Ling Chau JF; Wang X; Leong WF
J Cell Biochem; 2011 May; 112(5):1229-42. PubMed ID: 21465521
[TBL] [Abstract][Full Text] [Related]
10. Clinical trials with bisphosphonates.
Lombardi A; Santora AC
Ann Ital Med Int; 1992; 7(3 Suppl):158S-165S. PubMed ID: 1297394
[TBL] [Abstract][Full Text] [Related]
11. Medical management of Paget's disease of bone: indications for treatment and review of current therapies.
Siris ES; Lyles KW; Singer FR; Meunier PJ
J Bone Miner Res; 2006 Dec; 21 Suppl 2():P94-8. PubMed ID: 17229018
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.
Grewal VS; Fayans EP
Todays FDA; 2008 Aug; 20(8):38-41, 43-6. PubMed ID: 18767452
[TBL] [Abstract][Full Text] [Related]
13. Nitrogen-containing bisphosphonate mechanism of action.
Reszka AA; Rodan GA
Mini Rev Med Chem; 2004 Sep; 4(7):711-9. PubMed ID: 15379639
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates: from bench to bedside.
Russell RG
Ann N Y Acad Sci; 2006 Apr; 1068():367-401. PubMed ID: 16831938
[TBL] [Abstract][Full Text] [Related]
15. [Perspectives on therapy with diphosphonates in non-malignant diseases].
Willvonseder R; Resch H
Z Gerontol; 1990; 23(1):39-42. PubMed ID: 2183510
[TBL] [Abstract][Full Text] [Related]
16. Experimental basis for the use of bisphosphonates in Paget's disease of bone.
Fleisch H
Clin Orthop Relat Res; 1987 Apr; (217):72-8. PubMed ID: 3549097
[TBL] [Abstract][Full Text] [Related]
17. The pharmacology and therapeutic utility of bisphosphonates.
Lourwood DL
Pharmacotherapy; 1998; 18(4):779-89. PubMed ID: 9692651
[TBL] [Abstract][Full Text] [Related]
18. [Bisphosphonates and bone remodeling: effectiveness in Paget's disease, fibrous dysplasia and osteoporosis].
Chapurlat R; Meunier PJ
Rev Chir Orthop Reparatrice Appar Mot; 1998 Nov; 84(8):743-51. PubMed ID: 10192126
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates: an overview with special reference to alendronate.
Vasikaran SD
Ann Clin Biochem; 2001 Nov; 38(Pt 6):608-23. PubMed ID: 11732644
[TBL] [Abstract][Full Text] [Related]
20. [Bisphosphonates in pharmacotherapy of bone diseases].
Iur'ieva EA; Matkovskaia TA; Elagina IA; Stoliarov IuIu
Eksp Klin Farmakol; 2000; 63(3):74-9. PubMed ID: 10934603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
